Outcome of Patients with PSMA PET/CT Screening Failure by VISION Criteria and Treated with 177Lu-PSMA: A Multicenter Retrospective Analysis
Author:
Publisher
Society of Nuclear Medicine
Subject
Radiology, Nuclear Medicine and imaging
Reference10 articles.
1. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2. Morris MJ, De Bono JS, Chi KN, et al. Phase III study of lutetium-177-PSMA-6176 in patients with metastatic castrate resistant prostate cancer (VISION). J Clin Oncol. 2021;39:18s (LBA4).
3. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer;Tagawa;Cancer.,2019
4. Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC) [abstract];Tagawa;J Clin Oncol.,2021
5. Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings;Hummel;Immunotherapy.,2021
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy;Radiology;2024-04-01
2. Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives;Cancer Treatment Reviews;2024-03
3. Authors’ reply to Dr. Paolo Duarte: Combined [68Ga]Ga-PSMA-11 and low-dose [18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy;European Journal of Nuclear Medicine and Molecular Imaging;2022-12-22
4. Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy;European Journal of Nuclear Medicine and Molecular Imaging;2022-09-22
5. Role of Prostate-Specific Membrane Antigen PET in Metastatic Prostate Cancer: We Have the Answers;Journal of Nuclear Medicine;2022-06-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3